4 results
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
To investigate the causal involvement of the ralPFC in the offset of fear (study 1) and SSRT (study 2) by temporally inhibiting this area using transcranial magnetic stimulation (TMS).
The aim of the present study is to causally detect whether disrupting processing in the numerosity map with TMS alters numerosity perception and/or object size perception.
The primary objective of this clinical trial is to evaluate the safety and effectiveness of the AltaSeal® implants to provide bilateral mechanical occlusion of the fallopian tubes resulting prevention of pregnancy.